The diagnosis and treatment of venous thromboembolism in Asian patients

Thrombosis Journal

Table 3 Efficacy and safety outcomes of clinical trials with NOACs for the treatment of VTE

All Patients				Asian Patients
Trial	N	VTE recurrence^a	Major or CRNM bleeding^a	Trial	N	VTE recurrence^a	Major or CRNM bleeding^a
Dabigatran				Dabigatran
RE-COVER [114]	2539	1.10 (0.65–1.84)	0.63 (0.47–0.84)	RE-COVER RE-COVER II Asian subanalysis^b	557	2.55 (0.66–9.90)	0.63 (0.33–1.19)
RE-COVER II [115]	2568	1.08 (0.64–1.80)	0.62 (0.45–0.84)
Rivaroxaban				Rivaroxaban
EINSTEIN-DVT [116]	3449	0.68 (0.44–1.04)	0.97 (0.76–1.22)	EINSTEIN-DVT and PE Asian subanalysis [111]	439	1.04 (0.36–3.0)	0.63 (0.31–1.26)
EINSTEIN-PE [117]	4832	1.12 (0.75–1.68)	0.90 (0.76–1.07)	J-EINSTEIN DVT and PE [73]	100	3.9% (−3.4 to 23.8)^c	Rivaroxaban 7.8% UFH/warfarin 5.3%^d
Apixaban				Apixaban
AMPLIFY [119]	5395	0.84 (0.60–1.18)	0.44 (0.36–0.55)	AMPLIFY-J [112]	80	Apixaban 0/40 UFH/warfarin 1/40^e	Apixaban 7.5% UFH/warfarin 28.2%^f
Edoxaban				Edoxaban
Hokusai-VTE [120]	8240	0.89 (0.70–1.13)	0.81 (0.71–0.94)	Hokusai-VTE Asian subanalysis [110]	1109	0.64 (0.34–1.19)	0.56 (0.40–0.78)

^aValues are hazard ratio (95% confidence interval) unless otherwise indicated
^bData on file
^cAbsolute risk difference (95% confidence interval)
^dPercentage of patients with CRNM bleeding
^eNumber of patients
^fPercentage of patients
CRNM clinically relevant nonmajor, DVT deep vein thrombosis, NOAC non-vitamin K antagonist oral anticoagulant, PE pulmonary embolism, UFH unfractionated heparin, VTE venous thromboembolism

ISSN: 1477-9560